SUPN Supernus Pharmaceuticals Inc

Price (delayed)

$32.09

Market cap

$1.7B

P/E Ratio

15.21

Dividend/share

N/A

EPS

$2.11

Enterprise value

$1.84B

Highlights
Supernus Pharmaceuticals's revenue has increased by 38% YoY and by 7% from the previous quarter
The gross profit is up by 28% YoY and by 5% QoQ
The stock's price to earnings (P/E) is 45% more than its last 4 quarters average of 10.5 but 22% less than its 5-year quarterly average of 19.6
The quick ratio has contracted by 30% YoY and by 7% from the previous quarter
The EPS has declined by 12% since the previous quarter and by 4.5% year-on-year

Key stats

What are the main financial stats of SUPN
Market
Shares outstanding
53.02M
Market cap
$1.7B
Enterprise value
$1.84B
Valuations
Price to earnings (P/E)
15.21
Price to book (P/B)
2.25
Price to sales (P/S)
3.05
EV/EBIT
10.54
EV/EBITDA
9.31
EV/Sales
3.31
Earnings
Revenue
$556.35M
EBIT
$174.64M
EBITDA
$197.64M
Free cash flow
$163.26M
Per share
EPS
$2.11
Free cash flow per share
$3.08
Book value per share
$14.26
Revenue per share
$10.51
TBVPS
$20.23
Balance sheet
Total assets
$1.51B
Total liabilities
$753M
Debt
$394.57M
Equity
$754.44M
Working capital
$345.21M
Liquidity
Debt to equity
0.52
Current ratio
2.43
Quick ratio
2.15
Net debt/EBITDA
0.7
Margins
EBITDA margin
35.5%
Gross margin
88.6%
Net margin
20%
Operating margin
28.4%
Efficiency
Return on assets
7.4%
Return on equity
15.5%
Return on invested capital
18.7%
Return on capital employed
13.8%
Return on sales
31.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SUPN stock price

How has the Supernus Pharmaceuticals stock price performed over time
Intraday
-1.5%
1 week
2.85%
1 month
4.8%
1 year
34.49%
YTD
27.54%
QTD
22.57%

Financial performance

How have Supernus Pharmaceuticals's revenue and profit performed over time
Revenue
$556.35M
Gross profit
$493.09M
Operating income
$157.9M
Net income
$111.13M
Gross margin
88.6%
Net margin
20%
Supernus Pharmaceuticals's revenue has increased by 38% YoY and by 7% from the previous quarter
The net margin is down by 31% year-on-year and by 18% since the previous quarter
The gross profit is up by 28% YoY and by 5% QoQ
The company's operating margin fell by 25% YoY and by 15% QoQ

Growth

What is Supernus Pharmaceuticals's growth rate over time

Valuation

What is Supernus Pharmaceuticals stock price valuation
P/E
15.21
P/B
2.25
P/S
3.05
EV/EBIT
10.54
EV/EBITDA
9.31
EV/Sales
3.31
The stock's price to earnings (P/E) is 45% more than its last 4 quarters average of 10.5 but 22% less than its 5-year quarterly average of 19.6
The EPS has declined by 12% since the previous quarter and by 4.5% year-on-year
SUPN's price to book (P/B) is 55% less than its 5-year quarterly average of 5.0 but 25% more than its last 4 quarters average of 1.8
Supernus Pharmaceuticals's equity has increased by 23% YoY
The P/S is 40% below the 5-year quarterly average of 5.1 but 17% above the last 4 quarters average of 2.6
Supernus Pharmaceuticals's revenue has increased by 38% YoY and by 7% from the previous quarter

Efficiency

How efficient is Supernus Pharmaceuticals business performance
The return on sales has declined by 28% year-on-year and by 15% since the previous quarter
The return on assets has declined by 28% year-on-year and by 17% since the previous quarter
SUPN's return on invested capital is up by 25% year-on-year but it is down by 4.6% since the previous quarter
The company's return on equity fell by 24% YoY and by 17% QoQ

Dividends

What is SUPN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SUPN.

Financial health

How did Supernus Pharmaceuticals financials performed over time
Supernus Pharmaceuticals's total assets is 100% higher than its total liabilities
The company's total liabilities rose by 31% YoY
The quick ratio has contracted by 30% YoY and by 7% from the previous quarter
The debt is 48% smaller than the equity
Supernus Pharmaceuticals's equity has increased by 23% YoY
Supernus Pharmaceuticals's debt to equity has decreased by 16% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.